Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides

Nucleic Acids Research

Volumn 32, Issue 14, 2004, Pages 4411-4419

  Kang, Hyunmin ^a,b   Fisher, Michael H ^a   Xu, Dong ^a   Miyamoto, Yuko J ^a   Marchand, Arnaud ^c   Van Aerschot, Arthur ^c   Herdewijn, Piet ^c   Juliano, Rudolph L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Yongin University   (South Korea)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHOXYETHYL PHOSPHOROTHIOATE; ANTISENSE OLIGONUCLEOTIDE; CELL SURFACE PROTEIN; GENE PRODUCT; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GS 1954; GS 1955; GS 1956; GS 1957; GS 1962; GS 1964; LIPOFECTAMINE; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEASE; NUCLEIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; RHODAMINE 123; RIBONUCLEASE H; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FLUORESCENT DYE; NUCLEOTIDE; SUGAR ALCOHOL;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL SURFACE; CHIMERA; CONTROLLED STUDY; CORRELATION COEFFICIENT; DNA FLANKING REGION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PRIORITY JOURNAL; START CODON; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; ANIMAL; CELL LINE; CELL STRAIN 3T3; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; TRANSPORT AT THE CELLULAR LEVEL; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL LINE; FLOW CYTOMETRY; FLUORESCENT DYES; GENE EXPRESSION REGULATION; MICE; NIH 3T3 CELLS; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; RHODAMINE 123; SUGAR ALCOHOLS; THIONUCLEOTIDES;

EID: 4043059428     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkh775     Document Type: Article

References (66)

1. Ambudkar,S.V., Kimchi-Sarfaty,C., Sauna,Z.E. and Gottesman,M.M. (2003) P-glycoprotein: from genomics to mechanism. Oncogene, 22, 7468-7485.
2. Juliano,R.L. and Ling,V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455, 152-162.
3. Licht,T., Pastan,I., Gottesman,M. and Herrmann,F. (1994) P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann. Hematol., 69, 159-171.
4. Bradley,G. and Ling,V. (1994) P-glycoprotein, multidrug-resistance and tumor progression. Cancer Metastasis Rev., 13, 223-233.
5. Ambudkar,S.V., Dey,S., Hrycyna,C.A., Ramachandra,M., Pastan,I. and Gottesman,M.M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39, 361-398.
6. Thiebaut,F., Tsuruo,T., Hamada,H., Gottesman,M.M., Pastan,I. and Willingham,M.C. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl Acad. Sci. USA, 84, 7735-7738.
7. Garraway,L.A. and Chabner,B. (2002) MDR1 inhibition: less resistance or less relevance? Eur. J. Cancer, 38, 2337-2340.
8. Leith,C.P., Kopecky,K.J., Godwin,J., McConnell,T., Slovak,M.L., Chen,I.M., Head,D.R., Appelbaum,F.R. and Willman,C.L. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, 89, 3323-3329.
9. Kaye,S.B. (1998) Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr. Opin. Oncol., 10 (Suppl. 1), S15-S19.
10. Kankesan,J., Vanama,R., Yusuf,A., Thiessen,J.J., Ling,V., Rao,P.M., Rajalakshmi,S. and Sarma,D.S. (2003) Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis, 24, 1977-1984.
11. Sadanand, V., Kankesan,J., Yusuf,A., Stewart,C., Rutka,J.T., Thiessen,J.J., Ling,V., Rao,P.M., Rajalakshmi,S. and Sarma,D.S. (2003) Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitro. Cancer Lett., 198, 21-27.
12. Varma,M.V., Ashokraj,Y., Dey,C.S. and Panchagnula,R. (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res., 48, 347-359.
13. Sparreboom,A. and Nooter,K. (2000) Does P-glycoprotein play a role in anticancer drug pharmacokinetics? Drug Resist. Updat., 3, 357-363.
14. Kurreck,J. (2003) Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem., 270, 1628-1644.
15. Crooke,S.T. (2004) Progress in antisense technology. Annu. Rev. Med., 55, 61-95.
16. Agrawal,S. and Kandimalla,E.R. (2001) Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets, 1, 197-209.
17. Agrawal,S. and Kandimalla,E.R. (2000) Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today, 6, 72-81.
18. Dias,N. and Stein,C.A. (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther., 1, 347-355.
19. Stein,C.A. (2001) Antisense that comes naturally. Nat. Biotechnol., 19, 737-738.
20. Dean,N.M. and Bennett,C.F. (2003) Antisense oligonucleotide-based therapeutics for cancer. Oncogene, 22, 9087-9096.
21. Pirollo,K.F., Rait,A., Sleer,L.S. and Chang,E.H. (2003) Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther., 99, 55-77.
22. Herdewijn,P. (2000) Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acid Drug Dev., 10, 297-310.
23. Koshkin,A.A., Singh,S.K., Nielsen,P., Rajwanshi,V.K., Kumar,R., Meldgaard,M., Olsen,C.E. and Wengel,J. (1998) LNA (Locked Nucleic Acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron, 54, 3607-3630.
24. Nielsen,P.E., Egholm,M., Berg,R.H. and Buchardt,O. (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science, 254, 1497-1500.
25. Wang,J., Verbeure,B., Luyten,I., Lescrinier,E., Froeyen,M., Hendrix,C., Rosemeyer,H., Seela,F., Van Aerschot,A. and Herdewijn,P. (2000) Cyclohexene nucleic acids (CeNA): serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA. J. Am. Chem. Soc., 122, 8595-8602.
26. Miller,P.S. and Ts'o,P.O. (1987) A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: matagen (masking tape for gene expression). Anticancer Drug Des., 2, 117-128.
27. Levin,A.A. (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta, 1489, 69-84.
28. Zamaratski,E., Pradeepkumar,P.I. and Chattopadhyaya,J. (2001) A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H. J. Biochem. Biophys. Methods, 48, 189-208.
29. Larsen,H.J., Bentin,T. and Nielsen,P.E. (1999) Antisense properties of peptide nucleic acid. Biochim. Biophys. Acta, 1489, 159-166.
30. Agrawal,S. and Zhao,Q. (1998) Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev., 8, 135-139.
31. Peyman,A. and Uhlmann,E. (1996) Minimally modified oligonucleotides-combination of end-capping and pyrimidine-protection. Biol. Chem. Hoppe-Seyler, 377, 67-70.
32. Rait,A., Pirollo,K., Will,D.W., Peyman,A., Rait,V., Uhlmann,E. and Chang,E.H. (2000) 3′-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol: synthesis and anti-ras activity in radiation-resistant cells. Bioconjug. Chem., 11, 153-160.
33. Hamma,T. and Miller,P.S. (1999) Syntheses of alternating oligo-2′-O-methylribonucleoside methylphosphonates and their interactions with HIV TAR RNA. Biochemistry, 38, 15333-15342.
34. Alahari,S.K., DeLong,R., Fisher,M.H., Dean,N.M., Viliet,P. and Juliano,R.L. (1998) Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J. Pharm. Exp. Ther., 286, 419-428.
35. Alahari,S.K., Dean,N.M., Fisher,M.H., Delong,R., Manoharan,M., Tivel,K.L. and Juliano,R.L. (1996) Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol. Pharmacol., 50, 808-819.
36. Puerta-Fernandez,E., Romero-Lopez,C., Barroso-delJesus,A. and Berzal-Herranz,A. (2003) Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol. Rev., 27, 75-97.
37. Hannon,G.J. (2002) RNA interference. Nature, 418, 244-251.
38. Sioud,M. (2004) Therapeutic siRNAs. Trends Pharmacol. Sci., 25, 22-28.
39. Harborth,J., Elbashir,S.M., Vandenburgh,K., Manninga,H., Scaringe,S.A., Weber,K. and Tuschl,T. (2003) Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev., 13, 83-105.
40. Fire,A., Xu,S., Montgomery,M.K., Kostas,S.A., Driver,S.E. and Mello,C.C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391, 806-811.
41. Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K. and Tuschl,T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
42. Golub,T.R., Slonim,D.K., Tamayo,P., Huard,C., Gaasenbeek,M., Mesirov,J.P., Coller,H., Loh,M.L., Downing,J.R., Caligiuri,M.A. et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286, 531-537.
43. Semizarov,D., Frost,L., Sarthy,A., Kroeger,P., Halbert,D.N. and Fesik,S.W. (2003) Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl Acad. Sci. USA, 100, 6347-6352.
44. Scacheri,P.C., Rozenblatt-Rosen,O., Caplen,N.J., Wolfsberg,T.G., Umayam,L., Lee,J.C., Hughes,C.M., Shanmugam,K.S., Bhattacharjee,A., Meyerson,M. et al. (2004) Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl Acad. Sci. USA, 101, 1892-1897.
45. Sioud,M. and Sorensen,D.R. (2003) Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun., 312, 1220-1225.
46. Ramachandran,C. and Wellham,L.L. (2003) Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Anticancer Res., 23, 2681-2690.
47. Pakunlu,R.I., Cook,T.J. and Minko,T. (2003) Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pharm. Res., 20, 351-359.
48. Brigui,I., Djavanbakht-Samani,T., Jolles,B., Pigaglio,S. and Laigle,A. (2003) Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdr1. Biochem. Pharmacol., 65, 747-754.
49. Pan,L., Tong,Y., Jin,Y., Zhou,S., Zhang,Y., Yang,X. and Mao,N. (2001) Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides. Chin. Med. J. (Engl), 114, 929-932.
50. Fisher,A.A., Ye,D., Sergueev,D.S., Fisher,M.H., Shaw,B.R. and Juliano,R.L. (2002) Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. J. Biol. Chem., 277, 22980-22984.
51. Quattrone,A., Papucci,L., Morganti,M., Coronnello,M., Mini,E., Mazzei,T., Colonna,F.P., Garbesi,A. and Capaccioli,S. (1994) Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance. Oncol. Res., 6, 311-320.
52. Kobayashi,H., Takemura,Y. and Miyachi,H. (2001) Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics. Hum. Cell, 14, 172-184.
53. Nagata,J., Kijima,H., Hatanaka,H., Asai,S., Miyachi,H., Abe,Y., Yamazaki,H., Nakamura,M., Watanabe,N., Mine,T. et al. (2002) Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int. J. Oncol., 21, 1021-1026.
54. Kuznetsova,M., Fokina,A., Lukin,M., Repkova,M., Venyaminova,A. and Vlassov,V. (2003) Catalytic DNA and RNA for targeting MDR1 mRNA. Nucleosides Nucleotides Nucleic Acids, 22, 1521-1523.
55. Kobayashi,H., Dorai,T., Holland,J.F. and Ohnuma,T. (1993) Cleavage of human MDR1 mRNA by a hammerhead ribozyme. FEBS Lett., 319, 71-74.
56. Holm,P.S., Dietel,M. and Krupp,G. (1995) Similar cleavage efficiencies of an oligoribonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozyme. Gene, 167, 221-225.
57. Wu,H., Hait,W.N. and Yang,J.M. (2003) Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res., 63, 1515-1519.
58. Nieth,C., Priebsch,A., Stege,A. and Lage,H. (2003) Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett., 545, 144-150.
59. Hendrix,C., Rosemeyer,H., De Bouvere,B., Van Aerschot,A., Seela,F. and Herdewijn,P. (1997) 1′,5′-anhydrohexitol oligonucleotides: hybridisation and strand displacement with oligoribonucleotides, interaction with RNase H and HIV reverse transcriptase. Chemistry - A Eur. J., 3, 1513-1520.
60. Lescrinier,E., Esnouf,R., Schraml,J., Busson,R., Heus,H.A., Hilbers,C.W. and Herdewijn,P. (2000) Solution structure of a HNA-RNA hybrid. Chem. Biol., 7, 719-731.
61. Vandermeeren,M., Preveral,S., Janssens,S., Geysen,J., Saison-Behmoaras,E., Van Aerschot,A. and Herdewijn,P. (2000) Biological activity of hexitol nucleic acids targeted at Ha-ras and intracellular adhesion molecule-1 mRNA. Biochem. Pharmacol., 59, 655-663.
62. Flores,M.V., Atkins,D., Stewart,T.S., Van Aerschot,A. and Herdewijn,P. (1999) Antimalarial antisense activity of hexitol nucleic acids. Parasitol. Res., 85, 864-866.
63. De Bouvere,B., Kerremans,L., Rozenski,J., Janssen,G., Van Aerschot,A., Claes,P., Busson,R. and Herdewijn,P. (1997) Improved synthesis of anhydrohexitol building blocks for oligonucleotide synthesis. Liebigs Ann.-Rec., 1453-1461.
64. DeWinter,H., Lescrinier,E., Van Aerschot,A. and Herdewijn,P. (1998) Molecular dynamics simulation to investigate differences in minor groove hydration of HNA/RNA hybrids as compared to HNA/DNA complexes. J. Am. Chem. Soc., 120, 5381-5394.
65. Levesque,L., Dean,N.M., Sasmor,H. and Crooke,S.T. (1997) Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells. Mol. Pharmacol., 51, 209-216.
66. Kane,S.E., Reinhard,D.H., Fordis,C.M., Pastan,I. and Gottesman,M.M. (1989) A new vector using the human multidrug resistance gene as a selectable marker enables overexpression of foreign genes in eukaryotic cells. Gene, 84, 439-446.